Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BFH772 1% ointment
BFH772 1% · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BFH772 | EXPERIMENTAL | - |
| Vehicle | PLACEBO_COMPARATOR | - |
| Metronidazole | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BFH772 1% ointment | DRUG | - |
| Vehicle ointment | DRUG | - |
| Noritate® 1% cream | DRUG | - |
Inclusion Criteria: * Have persistent facial erythema on the cheeks of at least moderate severity. * Women must not be able to bear children Exclusion Criteria: * Have more than 12 inflammatory lesions on the face * Previous treatment of facial skin with lasers or electrocauterisation within 2 mo...
BFH772 1% is a topical small molecule being developed for erythemato-telangiectatic rosacea, a form of rosacea marked by persistent facial redness and visible blood vessels. It is applied as an ointment to the skin. The drug is in Phase 2 clinical development and is not approved for marketing.
BFH772 1% targets KDR, also known as vascular endothelial growth factor receptor 2. It acts as an inhibitor of this receptor. Because KDR signaling drives blood vessel growth and dilation, inhibiting it is the proposed approach for addressing the vascular features of erythemato-telangiectatic rosacea.
BFH772 1% is developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the clinical program evaluating the ointment in rosacea patients.
BFH772 1% is in Phase 2 development. It is an investigational drug and has not been approved by the FDA. The Phase 2 program has completed, with no trials currently listed as active.
BFH772 1% has been studied in one Phase 2 trial, NCT01449591, titled Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients. The trial enrolled 36 participants in the United States, was randomized, double blind, and placebo controlled, and has completed.
Yes. BFH772 1% and BFH772 1% ointment refer to the same investigational product from Novartis. The ointment designation describes the topical formulation used in the Phase 2 rosacea study, so searches for either name point to the same asset.